|
FY2025
12 months to Sep 30, 2025
|
FY2024
12 months to Sep 30, 2024
|
FY2023
12 months to Sep 30, 2023
|
FY2022
12 months to Sep 30, 2022
|
FY2021
12 months to Sep 30, 2021
|
|
|---|---|---|---|---|---|
| Grant income | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Gain on derivative instruments | |||||
| Other non-operating losses | |||||
| Interest expense, net | |||||
| Other expense | |||||
| Net loss | |||||
| Net loss | |||||
| Modification of warrants | |||||
| Net loss available to common shareholders | |||||
| Net loss per common share - basic and diluted | |||||
| Net loss per common share - basic and diluted | |||||
| Weighted average common shares outstanding - basic and diluted | |||||
Loading...